Chimeric Antigen Receptor trang 1 tải miễn phí từ tailieunhanh

"Chimeric Antigen Receptor" trang 1 - tải miễn phí từ tailieunhanh

Recent progress in improving the safety and efficacy of chimeric antigen receptor T cell therapy

Recent progress in improving the safety and efficacy of chimeric antigen receptor T cell therapy

10 52 0

Modulation of chimeric antigen receptor surface expression by a small molecule switch

Modulation of chimeric antigen receptor surface expression by a small molecule switch

9 86 0

$The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies: A meta-analysis$

The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies: A meta-analysis

13 33 1

Distribution of chimeric antigen receptormodified T cells against CD19 in B-cell malignancies

Distribution of chimeric antigen receptormodified T cells against CD19 in B-cell malignancies

10 35 1

Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment

Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment

9 12 1

Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in Lymphoma patients

Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in Lymphoma patients

9 6 1

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing

17 55 0

Activated iNKT cells enhance the antitumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer

Activated iNKT cells enhance the antitumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer

10 49 1

Tuning the performance of CAR T cell immunotherapies

Tuning the performance of CAR T cell immunotherapies

7 114 0

Optimized DNA electroporation for primary human T cell engineering

Optimized DNA electroporation for primary human T cell engineering

9 93 0

Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice

Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice

13 42 1

Challenges of driving CD30-directed CAR-T cells to the clinic

Challenges of driving CD30-directed CAR-T cells to the clinic

8 43 1

Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)

Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)

7 53 1

$Humanized CD19 CAR-T cells in relapsed/ refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy$

Humanized CD19 CAR-T cells in relapsed/ refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy

8 18 1

Pre-clinical research on the application of CAR-T therapy in the treatment of acute lymphoblastic leukemia

Pre-clinical research on the application of CAR-T therapy in the treatment of acute lymphoblastic leukemia

11 1 1

$Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients$

Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients

10 4 1

B7-H3 targeted CAR-T cells show highly efcient anti-tumor function against osteosarcoma both in vitro and in vivo

B7-H3 targeted CAR-T cells show highly efcient anti-tumor function against osteosarcoma both in vitro and in vivo

12 1 1

$Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy$

Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy

8 8 1